To elucidating nicolas sarkozy dating
Our leading drug candidate, designated as MP1000, is a nanoparticulate liposomal phospholipid immune-modulating agent that exhibits potent anti-cancer efficacy as well as a very low toxicity in animal models.In addition to progressing MP1000 through IND enabling studies and toward human clinical trials, we are developing next generation drug candidates to take advantage of our phospholipid platform in tumor specific drug delivery and immuno-oncology.The theme of the Conference “Transforming Challenges into Opportunities to Feed the Future” puts emphasis on the modern scientific and technological achievements and attempts to approach, in a creative way, future of industrial applications.
The conference is organized by Innovinc International with a various food science societies and associations.She is a medicinal chemist with a 10 years of experience most recently at Ironwood Pharmaceuticals, Cambridge, MA as well as other research organizations such as Ar Qule, Bayer, and Infinity Pharmaceuticals. The analysis of phospholipids in particular is challenging but Chris has more than 20 years of experience with working with phospholipids in whole array of different environments including living tissues and using state of the art methods and equipment to do so.She has authored several granted patents and patent applications, and has compounds that have moved forward into FDA trials. Prior joining Machavert, Chris was a lipidomic analysis expert at the Department of Pharmacology, School of Medicine, University of Colorado in a lab of Prof.IFHN-2018 is aimed to present an opportunity to all the experts in the field of Food and Nutrition to share the most recent progressions and difficulties in the field and bring together innovative academics and industrial experts in the field of Food Science and Nutrition to a common forum.Mark your calendars now and stay tuned for more information.